CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more


News and features about the latest developments in optics with a focus on industry

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more


Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Asthma medication stalls diabetic eye disease

US researchers report that montelukast inhibits early diabetic retinopathy changes in mice


New research suggests that a type of asthma medication could be investigated as a method of counteracting diabetic eye disease.

Researchers from University Hospitals Rainbow Babies and Children’s Hospital and Case Western Reserve University School of Medicine found that the asthma medication montelukast (Singulair) can inhibit early changes in diabetic retinopathy.

Writing in Diabetes, scientists describe how mice with diabetes were given the medication and diabetes-related retinal pathology was measured. A control group of mice with diabetes did not receive the medication.

The authors report that after nine months, the retinal microvasculature of untreated mice had a greater degree of degeneration than those that received montelukast.

“Montelukast inhibited the diabetes-induced capillary and neuronal degeneration, whether administered as a prevention strategy, immediately following induction of diabetes, or as an intervention strategy,” they highlighted.

Image credit: Pixabay